Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: Baskent University experience.

Köse, Fatih; Beşen, Ali Ayberk; Sümbül, Ahmet Taner; Sezer, Ahmet; Karadeniz, Ceyda; Dişel, Umut; Altundağ, Özden; Ozyilkan, Ozgür

doi:10.1200/jco.2011.29.15_suppl.e16001

Cited by 17 publications

(34 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The main reasons for this observation of some difference in toxicity could have been forced hydration and post-CT care of patients which was mandatory only for 3-weekly arm as suggested by the authors (Tsan et al, 2012). Similar findings were seen in a retrospective analysis of 55 patients by Kose et al demonstrating a higher incidence of grade III -IV mucositis with the weekly regimen (Kose et al, 2011). They reported that patients with grade III -IV mucositis during CRT had significantly higher median OS than those DOI:http://dx.doi.org/10.7314/APJCP.2016.17.4…”

Section: Acute Toxicity (Mucositis Dermatitis)supporting

confidence: 74%

See 1 more Smart Citation

Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma

Negi¹,

Kingsley²,

Srivastava³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cisplatin-based concurrent chemoradiation plays an undisputed key role as definitive treatment in unresectable patients with locally advanced squamous cell carcinoma head and neck or as an organ preservation strategy. Treatment with 100 mg/m2 3-weekly cisplatin is considered the standard of care but is often associated with several adverse events. The optimum drug schedule of administration remains to be defined and presently, there is insufficient data limiting conclusions about the relative tolerability of one regimen over the other. This review addresses regarding the optimal dose schedule of cisplatin focusing mainly on three-weekly and weekly dose of cisplatin based concurrent chemoradiotherapy in locally advanced head and neck cancer with an emphasis on mucositis, dermatitis, systemic toxicity, compliance, and treatment interruptions. To derive a definitive conclusion, large prospective randomized trials are needed directly comparing standard 3-weekly cisplatin (100 mg/m 2 ) with weekly schedule (30 -40 mg/m 2 ) of concurrent cisplatin based chemoradiotherapy in locally advanced squamous cell carcinoma head and neck.

show abstract

Section: Acute Toxicity (Mucositis Dermatitis)supporting

confidence: 74%

“…Contradictory to this, various studies have reported no difference in terms of hematological toxicities between the two comparative arms (Kose et al, 2011;Tsan et al, 2012).…”

Section: 1617 Three Weekly Versus Weekly Cisplatin As Radiosensitizementioning

confidence: 99%

Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma

Negi¹,

Kingsley²,

Srivastava³

et al. 2016

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…As published in 2012, Tsan et al randomized 55 postoperative high-risk SCCHN cases of the oral cavity between weekly and three-weekly regimens, demonstrating superiority of the latter scheme both in terms of compliance and toxicity [33]. Additionally, six studies retrospectively investigating the same comparison yielded outcomes favoring neither of these two schedules (Table 3) [26,[78][79][80][81][82].…”

Section: Resultsmentioning

confidence: 99%

Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data

et al. 2017

View full text Add to dashboard Cite

Given concurrently with conventional radiotherapy in locally advanced head and neck cancer, high-dose three-weekly cisplatin has often been replaced with weekly low-dose infusions to increase compliance and decrease toxicity. The present meta-analysis suggests that both approaches might be equal in efficacy, both in the definitive and postoperative settings, but differ in toxicity. However, some toxicity data can be influenced by unbalanced representation, and the conclusions are not based on adequately sized prospective randomized studies. Therefore, low-dose weekly cisplatin should not be used outside clinical trials but first prospectively studied in adequately sized phase III trials versus the high-dose three-weekly approach.

show abstract

“…It was reported that up to 87% of patients treated with weekly cisplatin reached grade≥3 toxicity [18, 27] and 57% in three weekly group [14, 17, 24, 28]. …”

Section: Discussionmentioning

confidence: 99%

A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC)

Guan

Zhang

et al. 2016

Oncotarget

View full text Add to dashboard Cite

PurposeThis study was performed to compare the efficacies and acute toxicities in weekly- and three weekly- cisplatin based concurrent chemoradiotherapy (CCRT) for advanced HNC patients.Results779 patients of 10 studies were eligible. No difference in the 2-, 3-year OS or 1-, 2-year LRFS was observed, whereas patients in three weekly CCRT arm tended to have a better 5-year OS (HR=1.79, 95%C 0.97-3.31, p=0.06). Weekly arm seemed to show less gastrointestinal toxicities (RR=0.59, 95%CI 0.34-1.02, p=0.06), but similar hematologic toxicity compared to three weekly arm. Subgroup analysis displayed more grade ≥3 mucositis (RR=1.72, p=0.01), and more chemotherapy related delay/interrupt (RR=2.68, p<0.0001) in weekly arm for non-nasopharynx carcinoma (non-NPC) HNC.MethodsWe conducted the meta-analysis by searching PubMed, MEDLINE, ScienceDirect, Cochrane Library and China National Knowledge Infrastructure (CNKI) databases. The primary endpoint was overall survival (OS) with secondary endpoints locoregional recurrence-free survival (LRFS) and grade≥3 acute adverse events. RevMan 5.2 was used to perform statistical analyses.ConclusionsThree weekly cisplatin-based CCRT might achieve a higher long-term OS with no significant difference in a shorter OS and LRFS. Weekly arm was associated with less gastrointestinal toxicities but more grade≥3 mucositis and chemotherapy related delay/interrupt. Large randomized trials were urgent to further define superiority of these two regimens.

show abstract

Weekly cisplatin versus standard three-weekly cisplatin in concurrent chemoradiotherapy of head and neck cancer: Baskent University experience.

Abstract: Cooper et al., 2004). This regimen is, however, usually associated with significant increase in acute toxicities such as higher rate of mucositis, hematological complication, and renal complication. Occurrence of these side effects can be resulted with early treatment termination or at

Cited by 17 publications

References 11 publications

Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma

Three Weekly Versus Weekly Cisplatin as Radiosensitizer in Head and Neck Cancer: a Decision Dilemma

Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data

A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC)

Contact Info

Product

Resources

About